logo

Myriad Genetics Inc. (MYGN)



Trade MYGN now with
  Date
  Headline
1/3/2018 7:06:32 AM Myriad Genetics Reports Expanded Research Collaboration With AstraZeneca
12/12/2017 7:06:41 AM Myriad: BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients Who Responded To Talazoparib
11/10/2017 7:07:45 AM Myriad Collaborates With Dept Of VA In Trial Evaluating GeneSight Test To Improve Mental Health Outcomes For Veterans3
11/7/2017 4:07:00 PM Myriad Genetics Q1 GAAP EPS $1.15 And Adjusted EPS $0.26
11/6/2017 7:06:59 AM Myriad Genetics Partners With CareFirst BlueCross BlueShield On CED Study For Vectra DA Test
10/24/2017 7:12:49 AM Myriad Submits BRACAnalysis CDx Application For Regulatory Approval In Japan For HER2- Metastatic Breast Cancer
10/19/2017 7:12:13 AM Assurex Health Announces New Positive Results For GeneSight Test In Patients With Generalized Anxiety Disorder
10/18/2017 7:03:10 AM Myriad’ BRACAnalysis CDx SPMA Accepted ByFDA For Review As Companion Diagnostic For Lynparza In Metastatic Breast Cancer
9/15/2017 7:11:02 AM Myriad Genetics Reports Positive Data Supporting New RiskScore Test
8/8/2017 4:08:58 PM Myriad Genetics Q4 EPS $0.19 Vs. $0.32 Year Ago